問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

5272Cases

2025-01-21 - 2032-12-31

Phase I/II

Active
A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    Freeze-dried injection

Participate Sites
3Sites

Recruiting3Sites

2025-02-01 - 2033-12-31

Phase III

Active
A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer (TroFuse-022/ENGOT-ov84/GOG-3103)

  • Condition/Disease

    Ovarian Cancer

  • Test Drug

    Injectables Injectables Oral solutions

Participate Sites
5Sites

Recruiting5Sites

2025-02-01 - 2030-12-31

Active
A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR)

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    Tablets; Hard capsules

Participate Sites
4Sites

Recruiting4Sites

2025-09-15 - 2036-04-30

Phase III

Not yet recruiting
A randomized, double-blind, placebo-controlled phase III trial is evaluating adjuvant saruparib (AZD5305) (EvoPAR-Prostate02) in patients with locally high-risk prostate cancer of the breast cancer gene mutation (BRCAm) who are currently receiving radiation therapy and androgen deprivation therapy.

  • Condition/Disease

    Metastasis-free survival (MFS) [Time range: approximately 93 months] - MFS is defined as the time elapsed from the date of randomization until the day of first diagnosis of distant metastasis as assessed by BICR (confirmed by standard clinical imaging [CT/MRI and bone scan, or PSMA-PET]) or death from any cause.

  • Test Drug

    AZD5305

Participate Sites
8Sites

Recruiting8Sites

2025-09-15 - 2030-12-31

Active
A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial investigating the efficacy and safety of TRONTINEMAB in patients with early symptomatic Alzheimer's disease (mild cognitive impairment to mild dementia caused by Alzheimer's disease).

  • Condition/Disease

    Changes in CDR-SB from the base period to week 72

  • Test Drug

    trontinemab

Participate Sites
8Sites

Recruiting8Sites

2025-09-22 - 2029-03-18

Active
The master plan for an open-label, multi-drug, multicenter, phase II trial evaluates the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity (LIBRA) of a novel combination therapy in participants with locally advanced or metastatic non-small cell lung cancer.

  • Condition/Disease

    • Safety: Number of participants experiencing adverse events (AEs) and serious adverse events (SAEs). • Efficacy: Objective response rate (ORR).

  • Test Drug

    Dato-DXd Rilvegostomig Xinruize

Participate Sites
9Sites

Recruiting9Sites

2025-09-24 - 2028-11-30

Phase I

Active
A first-in-human, phase 1, open-label, multicenter trial of a novel phosphatidylinositol glycan-3 target antibody-drug complex, ZW251, in participants with advanced solid tumors including hepatocellular carcinoma.

  • Condition/Disease

    Including advanced solid tumors such as hepatocellular carcinoma

  • Test Drug

    ZW251

Participate Sites
3Sites

Recruiting3Sites

2025-09-30 - 2027-06-30

Phase II

Active
A phase 2, randomized, double-blind, placebo-controlled proof-of-concept trial was conducted to evaluate the efficacy and safety of EI-001 in patients with non-segmented vitiligo.

  • Condition/Disease

    • Percentage change of F-VASI relative to baseline in week 24

  • Test Drug

    EI-001

Participate Sites
2Sites

Recruiting2Sites

2025-10-01 - 2030-06-30

Active
EASi-PROTKT™ is a phase III, double-blind, randomized, parallel-group superiority trial evaluating the efficacy and safety of oral vicadrostat (BI 690517) combined with empagliflozin compared to placebo combined with empagliflozin in participants with type 2 diabetes, hypertension, and a history of cardiovascular disease.

  • Condition/Disease

    • The time elapsed before the first occurrence of a CV death or HFE (defined as HHF or emergency HF visit). CV deaths include deaths of unknown cause.

  • Test Drug

    BI 690517 (Vicadrostat) or matching placebo Empagliflozin

Participate Sites
13Sites

Recruiting13Sites

2025-10-01 - 2035-01-20

Active
Beamion LUNG-3: A randomized, controlled, multicenter trial evaluating zongertinib as adjuvant monotherapy versus standard of care in patients with early-stage, resectable non-small cell lung cancer (stage II-IIIB) and HER2 mutations with activated tyrosine kinase domain.

  • Condition/Disease

    DFS as assessed by the trial administrator. DFS is defined as the time elapsed from randomization until tumor recurrence or death from any cause (whichever occurs earlier).

  • Test Drug

    Imfinzi® KEYTRUDA® OPDIVO Tecentriq® Zongertinib (BI 1810631)

Participate Sites
6Sites

Recruiting6Sites

1 2 3 4 5 528
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB